Urology

Uncomplicated Urinary Tract Infections

Advertisement

Multidrug Resistance in Uncomplicated Urinary Tract Infections

expert roundtables by Anne P. Cameron, MD, FRCSC, URPS; Loren G. Miller, MD, MPH; Anthony J. Schaeffer, MD
Overview

Multidrug-resistant urinary tract infections (UTIs) are increasingly common, even among patients without significant prior health care exposure. Resistance can complicate empiric treatment and limit oral antibiotic options. Appropriate diagnosis, the selective use of urine cultures, the recognition of individual and local resistance patterns, the use of antibiotic stewardship, and careful antibiotic selection are increasingly important to effectively manage uncomplicated UTIs.

What is the current landscape of antibiotic drug resistance, and what are some strategies to address rising multidrug resistance in uncomplicated UTIs?
“I remind providers that the diagnosis of a UTI should really be based on the patient’s clinical symptoms and not just on a laboratory test. . . . a good antibiotic steward should first make sure that they have the right diagnosis.”
— Loren G. Miller, MD, MPH

Antibiotic-resistant pathogens that cause UTIs have become increasingly common. Decades ago, they were mostly limited to patients who were hospitalized or to those with extensive health care exposure. But now, many community-acquired uncomplicated UTIs are caused by pathogens that are already resistant to commonly used oral antibiotics. Thus, unfortunately, we are now in an era in which patients do not need to have significant health care exposure to be infected with a highly resistant uropathogen.

 

At Harbor-UCLA Medical Center, our antibiotic stewardship team uses antibiograms to obtain an overall sense of resistance patterns in our community. However, just because there is high susceptibility to a drug, this does not necessarily mean that it is an ideal drug. Some antibiotics, such as trimethoprim-sulfamethoxazole, inherently work well for UTI treatment. And others, such as cephalexin, may be less preferred. So, the percent susceptibility tells only part of the story. We encourage providers to also consider using the antibiotics that are recommended first line by the Infectious Diseases Society of America (IDSA).

 

Another educational piece for providers is that UTIs are really a clinical diagnosis rather than a laboratory diagnosis. Many patients will say something like, “Well, I did not know that I had a UTI until they did a test,” because they did not have frequency, dysuria, urgency, or any other signs or symptoms of a UTI. I remind providers that the diagnosis of a UTI should really be based on the patient’s clinical symptoms and not just on a laboratory test. Otherwise, providers may overdiagnose UTIs because bacteria can be detected in urine cultures due to contamination, which is common, particularly among women. Bacteria can also be detected because the patient may have asymptomatic bacteriuria, which is increasingly common with age, especially in women. So, a good antibiotic steward should first make sure that they have the right diagnosis.

“. . . it is not only the resistance documented in the local antibiogram that we can use but also the individual patient’s documented resistance pattern, which can be very helpful in making future antibiotic-related decisions.”
— Anne P. Cameron, MD, FRCSC, URPS

Things used to be fairly straightforward when a patient presented with an uncomplicated UTI, meaning someone with lower urinary tract symptoms that were consistent with a UTI who was otherwise healthy, did not catheterize, and had no fever, flank pain, or anything else to suggest that something unusual was going on. In those patients, you were able to choose an empiric antibiotic based on the local antibiogram and successfully treat them (most of the time) without culture results. But now, with antibiotic resistance occurring more often in many patients, you are often choosing the wrong antibiotic empirically. Something that used to be clinically very straightforward is now much more complicated.

 

At the University of Michigan, we have partnered with our infectious disease colleagues to come up with a roadmap. When a patient calls our clinic to report UTI symptoms, nurses perform a chart review to document their symptoms, history, and any risk factors they might have. This information is then passed on to the clinician who decides what to do next. As part of this process at our clinic, all patients undergo a urinalysis and urine culture to document the presence or absence of a UTI, even if they are prescribed an antibiotic empirically. Then, the clinician can look back and know whether that antibiotic was appropriate. If the culture comes back negative, the clinician knows that they can stop the antibiotic; it also serves to document the resistance pattern and can provide guidance on what to do the next time the patient calls in. So, it is not only the resistance documented in the local antibiogram that we can use but also the individual patient’s documented resistance pattern, which can be very helpful in making future antibiotic-related decisions.

 

Patient education is also very important. We provide patients with a detailed handout that includes information not only on what to expect with an uncomplicated UTI but also emphasizing that we do not routinely test for cure. There is no culture after treatment with antibiotics because it is not a helpful test and can instead just encourage unnecessary antibiotic usage. It is important to empower patients to refuse urine cultures when they know that they are not needed.

“. . . I think that we need to really focus on accurately diagnosing a patient with UTI symptoms to make sure they actually have an infection and then try limiting therapy to the lowest level of drug exposure to not increase resistance.”
— Anthony J. Schaeffer, MD

I have had a significant awakening over the past several years. We started a complex UTI clinic at Northwestern under the assumption that referring providers would send us patients with recurrent documented UTIs, and we would then help treat those patients. Surprisingly, we learned that approximately 25% to 30% of these patients had never had a UTI documented by a culture. I think that, although we all follow the recommendations regarding times when you can treat a healthy patient with a straightforward UTI without a culture, recurrent infections and more complex situations should necessitate obtaining cultures.

 

So, I think that we need to really focus on accurately diagnosing a patient with UTI symptoms to make sure they actually have an infection and then try limiting therapy to the lowest level of drug exposure to not increase resistance. The complicated part is helping a patient understand this, because they may be very keen on getting antibiotic therapy for their presumed infection.

 

Something we have also learned about within our complex UTI clinic is the wide range of insights provided by the health care team. Our team consists of urologists, infectious disease specialists, and pharmacists, all of whom have significant insights that are very helpful when treating patients. A patient’s past culture and sensitivity are very good predictors of their current situation, so even though your therapy may be empiric, it can be guided and influenced by prior results.

 

Local antibiograms can be very specific, so we encourage our team to look at the antibiograms for outpatients, inpatients, patients from a rehabilitation institute, and patients from hospital intensive care units. Then, even when you have to use empiric therapy, it is guided by a background that is more consistent with where your patient probably acquired the infection. The clinician should ask questions to determine the likely source of the bacteria; if there is an antibiogram available that compliments that, those data can help you.

References

Ackerman AL, Bradley M, D’Anci KE, Hickling D, Kim SK, Kirkby E. Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline (2025). J Urol. 2026;215(1):3-12. doi:10.1097/JU.0000000000004723

 

Adamkova V, Matouskova M, Adamkova VG, Huptych M, Fontana M. The role of stratified cumulative antibiograms in the (choice of appropriate antibiotics in urinary tract infection) management of urinary tract infections. Pathogens. 2025;14(2):141. doi:10.3390/pathogens14020141

 

Chopra T, Tillotson G, Donald A. The changing picture of community acquired urinary tract infections in the US: a daunting prospect. Expert Rev Anti Infect Ther. 2026;24(9):845-853. doi:10.1080/14787210.2026.2695445

 

Collazo A, Wermuth P, Luna Rodriguez J, et al. ‘In Texas, everybody wants antibiotics’: reducing inappropriate antibiotic expectations and use with a provider-patient communication tool in primary care. Fam Med Community Health. 2025;13(4):e003628. doi:10.1136/fmch-2025-003628

 

Fromer DL, Luck ME, Cheng WY, et al. Risk factors for empiric treatment failure in US female outpatients with uncomplicated urinary tract infection: an observational study. J Gen Intern Med. 2025;40(4):862-870. Published correction appears in J Gen Intern Med. Published online December 16, 2024.

 

Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257

 

Khasawneh RA, Almomani BA, Al-Shatnawi SF, Al-Natour L. Clinical utility of prior positive cultures to optimize empiric antibiotic therapy selection: a cross-sectional analysis. New Microbes New Infect. 2023;55:101182. doi:10.1016/j.nmni.2023.101182

 

Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):1611-1615. doi:10.1093/cid/ciz021

Anne P. Cameron, MD, FRCSC, URPS

James Montie Legacy Professor of Urology
Vice Chair of Faculty Affairs
Service Chief
Department of Urology
University of Michigan Medical School
Ann Arbor, MI

Loren G. Miller, MD, MPH

Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA
Chief, Division of Adult Infectious Diseases
Harbor-UCLA Medical Center
Associate Site Director
UCLA Clinical and Translational Science Institute
Harbor-UCLA/Lundquist Institute Campus
Torrance, CA

Anthony J. Schaeffer, MD

Professor, Department of Urology
Herman L. Kretschmer Professor of Urology
Northwestern University Feinberg School of Medicine
Chicago, IL

Advertisement